Boston, MA's BANS Rated 'SP-1+', Bonds Rated 'AA-'; Outlook Stable Feb 02

  • ID: 2088113
  • February 2002
  • Standard & Poors
1 of 3

NEW YORK (Standard & Poor's) Feb. 11, 2002--Standard & Poor's today assigned it's 'SP-1'-plus rating to Boston, Mass.' $62 million BANs series 2002A due Feb 1, 2006. In addition, Standard & Poor's assigned its double-'A'-minus rating to the city's $100 million GO bonds series 2002A due Feb. 1, 2022. At the same time, Standard & Poor's affirmed its 'SP-1'-plus rating on the city's outstanding notes, as well as its double-'A'-minus rating and double 'A'-minus underlying rating (SPUR) on the city's outstanding bonds. The rating on the GO bonds reflects the city's: -- Slowing but nonetheless robust economy demonstrating signs of deceleration after several years of remarkable growth in employment, property values, and new construction; -- Strong financial cushion due to...

Companies mentioned in this report are:
- Boston

Action: New Rating

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3


Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown


  • Quick Help: This Credit Rating Report will be emailed to you.


If you have a more general question about our products please try our



Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer, Inc.